堃博醫療-B(02216.HK)擬270萬美元收購Fibernova100%股權
格隆匯9月8日丨堃博醫療-B(02216.HK)公吿,於2023年9月8日,公司與賣方(Dinova Healthcare、Kirma、徐波及Nahmias)訂立買賣協議,據此,公司已同意收購而賣方已同意出售目標公司Fibernova Holding Corporation的100%股權,總代價為270萬美元。總代價將以以下方式支付:(i)公司於完成時向賣方支付購買代價;(ii)公司於里程碑條件獲達成後就餘額向賣方支付里程碑付款。
目標公司從事開發首個光纖導航及成像系統的業務,用於醫療程序中各種導管或內窺鏡。該技術旨在於手術過程中實現周圍組織器官的實時顯示,並尋求滿足市場對光纖光柵(FBG)技術實現的精確及安全手術導航的需求。
集團與目標公司從事類似業務,因此,目標公司的業務與集團的業務整合將產生巨大的協同效應。
首先,集團的現有技術(包括肺部射頻消融系統、靶向肺去神經系統及冷凍消融系統)包括基於導管的介入治療解決方案。尤其是,集團從事器械生產,旨在於手術過程中提供準確實時導航。公司附屬公司堃博杭州為介入呼吸病理學領域的開拓者,提供基於導管的產品。
肺部手術通常涉及(其中包括)患者在局部麻醉時的呼吸運動引起的成像錯誤。因此,手術過程中的精準度大幅降低,需要多次掃描確認針頭的放置,從而增加了手術時間、輻射劑量及併發症發生率。儘管公司目前使用電腦斷層掃描(CT)及其他技術及方法進行術中導航及定位,以應對手術過程中的呼吸運動的影響,但上述問題仍無法完全消除。
其次,目標公司專注於開發源自以色列內蓋夫本古裏安大學(Ben-Gurion University of the Negev)所作的光纖技術。該光纖技術具有高臨牀價值,原因是其為實時傳感技術,為醫生提供有關導管在體內精確形狀及位置的反饋,與實時影像技術相輔相成。
透過收購事項,公司尋求利用目標公司的光纖技術提高其自身產品的精準度。收購事項將豐富及加強公司的產品組合,促進其技術發展,併為公司提供接觸於光學醫療設備領域擁有寶貴專業知識的人員的渠道。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.